Priscilla Sugianto, MD
Priscilla Sugianto, MD
Priscilla Sugianto is currently a Principal at Vivo Capital and serves on the boards of Inspirna, Adaxion Therapeutics, and Clasp Therapeutics. Prior to Vivo, Priscilla worked at CBC Group (fka C-Bridge Capital), as an Assistant Vice President on the Investment team where she was involved in all biopharma investment processes. In addition to equity investment, she was also involved in licensing, royalty, debt, and cross-border transactions. Priscilla was part of the founding team of Everest Medicines and AffaMed Therapeutics, supporting both companies in business development, corporate development, strategy, and fundraising/IPO process. She served on the board of Ocelot Bio, as well as board observers of Akira Bio, Bonum Therapeutics, Cerebral Therapeutics, Lenz Therapeutics, and Graybug Vision. Priscilla also has experience in the digital health space, with companies such as Flare Capital, Doctor on Demand, and Virta Health. Priscilla received her B.S. in Biochemistry, summa cum laude, from University of California Los Angeles. She earned her M.D. from Stanford University School of Medicine and M.B.A from Stanford Graduate School of Business. While at Stanford and UCLA, she undertook research in drug discovery in hematology, oncology, and dermatopathology under the support of NSF, NIH, and Amgen. Her work has been published in multiple peer-reviewed journals.